Pages that link to "Q34701722"
Jump to navigation
Jump to search
The following pages link to The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. (Q34701722):
Displaying 50 items.
- Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews (Q24202563) (← links)
- Antiepileptic drugs for neuropathic pain and fibromyalgia (Q24202629) (← links)
- Lacosamide for neuropathic pain and fibromyalgia in adults (Q24203727) (← links)
- Lacosamide for neuropathic pain and fibromyalgia in adults (Q24234774) (← links)
- Development of lacosamide for the treatment of partial-onset seizures (Q24629140) (← links)
- Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety (Q24644936) (← links)
- Lacosamide: what can be expected from the next new antiepileptic drug? (Q24655596) (← links)
- Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide (Q27014744) (← links)
- The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials (Q27026195) (← links)
- Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions (Q28245021) (← links)
- Nav 1.4 slow-inactivation: is it a player in the warm-up phenomenon of myotonic disorders? (Q28284919) (← links)
- Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine (Q28293492) (← links)
- Fast- or slow-inactivated state preference of Na+ channel inhibitors: a simulation and experimental study (Q28474487) (← links)
- Phenytoin inhibits the persistent sodium current in neocortical neurons by modifying its inactivation properties (Q28485346) (← links)
- Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders (Q28833549) (← links)
- Understanding Sodium Channel Function and Modulation Using Atomistic Simulations of Bacterial Channel Structures. (Q30392501) (← links)
- Modulation of sodium channel inactivation gating by a novel lactam: implications for seizure suppression in chronic limbic epilepsy (Q30437522) (← links)
- Ion conduction and conformational flexibility of a bacterial voltage-gated sodium channel (Q30573814) (← links)
- Brivaracetam differentially affects voltage-gated sodium currents without impairing sustained repetitive firing in neurons (Q30627739) (← links)
- Neuroprotective Effect of Lacosamide on Hypoxic-Ischemic Brain Injury in Neonatal Rats (Q33567241) (← links)
- Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis. (Q33568213) (← links)
- Differential regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by GSK3ß and CDK5 following traumatic brain injury. (Q33671879) (← links)
- Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities (Q33840785) (← links)
- Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity (Q33873552) (← links)
- The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth (Q33944532) (← links)
- Substituted N-(biphenyl-4'-yl)methyl (R)-2-acetamido-3-methoxypropionamides: potent anticonvulsants that affect frequency (use) dependence and slow inactivation of sodium channels (Q33951922) (← links)
- Liquid chromatography-tandem mass spectrometry for quantification of lacosamide, an antiepileptic drug, in rat plasma and its application to pharmacokinetic study (Q33953530) (← links)
- The structure-activity relationship of the 3-oxy site in the anticonvulsant (R)-N-benzyl 2-acetamido-3-methoxypropionamide (Q34052009) (← links)
- In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation (Q34055749) (← links)
- Low-dose lacosamide-induced atrial fibrillation: Case analysis with literature review (Q34114744) (← links)
- Lacosamide for the prevention of partial onset seizures in epileptic adults (Q34122954) (← links)
- Prevention of posttraumatic axon sprouting by blocking collapsin response mediator protein 2-mediated neurite outgrowth and tubulin polymerization. (Q34203586) (← links)
- Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels. (Q34402820) (← links)
- Pharmacological management of epilepsy: recent advances and future prospects (Q34823174) (← links)
- Development and characterization of novel derivatives of the antiepileptic drug lacosamide that exhibit far greater enhancement in slow inactivation of voltage-gated sodium channels. (Q34865999) (← links)
- Sodium channel slow inactivation as a therapeutic target for myotonia congenita (Q35044306) (← links)
- Clinical utility of eslicarbazepine: current evidence. (Q35087964) (← links)
- Merging Structural Motifs of Functionalized Amino Acids and α-Aminoamides Results in Novel Anticonvulsant Compounds with Significant Effects on Slow and Fast Inactivation of Voltage-gated Sodium Channels and in the Treatment of Neuropathic Pain (Q35099293) (← links)
- Intracellular gold nanoparticles increase neuronal excitability and aggravate seizure activity in the mouse brain (Q35119975) (← links)
- Inhibition of Neuronal Voltage-Gated Sodium Channels by Brilliant Blue G (Q35122828) (← links)
- Identification of a lacosamide binding protein using an affinity bait and chemical reporter strategy: 14-3-3 ζ. (Q35142055) (← links)
- Chimeric agents derived from the functionalized amino acid, lacosamide, and the α-aminoamide, safinamide: evaluation of their inhibitory actions on voltage-gated sodium channels, and antiseizure and antinociception activities and comparison with lac (Q35212961) (← links)
- VOLTAGE-GATED CALCIUM CHANNELS ARE NOT AFFECTED BY THE NOVEL ANTI-EPILEPTIC DRUG LACOSAMIDE. (Q35227081) (← links)
- Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action (Q35664957) (← links)
- Chimeric derivatives of functionalized amino acids and α-aminoamides: compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels. (Q35706539) (← links)
- Role of the local anesthetic receptor in the state-dependent inhibition of voltage-gated sodium channels by the insecticide metaflumizone (Q35776729) (← links)
- Post-translational modifications of voltage-gated sodium channels in chronic pain syndromes (Q36249467) (← links)
- Novel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathy (Q36329924) (← links)
- New developments in the treatment of partial-onset epilepsy (Q36337897) (← links)
- Identification of the benzyloxyphenyl pharmacophore: a structural unit that promotes sodium channel slow inactivation (Q36479712) (← links)